Needham Reiterates Buy on Cidara Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a price target of $3.
September 08, 2023 | 8:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Cidara Therapeutics and maintained a price target of $3.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $3 price target could potentially boost investor confidence in Cidara Therapeutics, leading to a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100